Candida News and Research RSS Feed - Candida News and Research

Europe has increasing prevalence of fungal resistance, warns ESCMID

Europe has increasing prevalence of fungal resistance, warns ESCMID

The European Society of Clinical Microbiology and Infectious Disease – an organization that explores the risks and best practices in infectious disease – is imploring global healthcare professionals and bodies to take a more active role in the growing problem of fungal resistance. [More]
3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the entire equity interest in Zhejiang Wansheng Pharmaceutical Co., Ltd a limited liability company incorporated in the PRC for an aggregate consideration of RMB 528 million. [More]
Researchers discover role of RORC mutations in patients with candidiasis and mycobacteriosis

Researchers discover role of RORC mutations in patients with candidiasis and mycobacteriosis

The discovery of bi-allelic mutations in RORC in patients with candidiasis and mycobacteriosis revealed the pivotal role of RORC in mucocutaneous immunity to Candida and in systemic immunity to Mycobacterium in humans. [More]
WPI-led study provides clues to new ways to treat difficult-to-cure fungal infections

WPI-led study provides clues to new ways to treat difficult-to-cure fungal infections

A study by a multidisciplinary research team, co-directed by Worcester Polytechnic Institute, offers new insights into how virulent fungi adapt through genetic modifications to fight back against the effects of medication designed to block their spread, and how that battle leaves them temporarily weakened. These insights may provide clues to new ways to treat notoriously difficult-to-cure fungal infections like thrush and vaginitis. [More]
3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the ex-China global rights to Apexigen's anti-TNF monoclonal antibody ("mAb") technology. 3SBio previously acquired the China rights from Apexigen in 2006. [More]
Enhancing body's gut defense system can reverse bloodstream infections

Enhancing body's gut defense system can reverse bloodstream infections

An upset in the body's natural balance of gut bacteria that may lead to life-threatening bloodstream infections can be reversed by enhancing a specific immune defense response, UT Southwestern Medical Center researchers have found. [More]
Airway granulocytes potential CF biomarker for fungal lung disease

Airway granulocytes potential CF biomarker for fungal lung disease

Researchers have found that accumulation in the airways of CXCR4+ granulocytes is associated with chronic colonisation by the fungus Aspergillus fumigatus. [More]
Winners of GSA poster awards announced at Fungal Genetics Conference

Winners of GSA poster awards announced at Fungal Genetics Conference

The Genetics Society of America and the community of fungal geneticists are pleased to announce the winners of the GSA poster awards at the 28th Fungal Genetics Conference, which took place in Pacific Grove, CA, March 17-22, 2015. [More]
Nielsen BioSciences launches skin test that helps physicians manage Valley Fever infections

Nielsen BioSciences launches skin test that helps physicians manage Valley Fever infections

Nielsen BioSciences announced today the launch of SPHERUSOL (Coccidioides immitis Spherule-Derived Skin Test Antigen), a skin test that provides valuable data to physicians managing Valley Fever infections. SPHERUSOL has been approved by the U.S. Food and Drug Administration as the only skin test to detect an immune response to the fungus called Coccidioides, or "cocci," in patients with history of the disease. [More]
New study describes economic consequences of using T2Candida Panel for detection of candidemia

New study describes economic consequences of using T2Candida Panel for detection of candidemia

A new study describes a model that estimates the economic consequences of using the T2Candida Panel (a novel diagnostic product that provides Candida detection) as an adjunct to the current blood culture-based diagnostic strategy in a high-risk hospital patient cohort. [More]
New approach could help identify novel drug targets to combat lethal fungal infections

New approach could help identify novel drug targets to combat lethal fungal infections

By modifying the CRISPR-Cas genome editing system, Whitehead Institute researchers are now able to manipulate Candida albicans' genome systematically--an approach that could help identify novel targets for therapies against this serious pathogen for which there are a limited number of anti-fungal agents. [More]
New research reveals how a deadly fungus grows and kills immune cells

New research reveals how a deadly fungus grows and kills immune cells

New research from the University of Toronto has scientists re-thinking how a lethal fungus grows and kills immune cells. The study hints at a new approach to therapy for Candida albicans, one of the most common causes of bloodstream infections. [More]
Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials. [More]
Case Western dental researcher discovers new way to model how T cells cause inflammation in mice

Case Western dental researcher discovers new way to model how T cells cause inflammation in mice

Case Western Reserve University dental researcher Pushpa Pandiyan has discovered a new way to model how infection-fighting T cells cause inflammation in mice. [More]
Fungal infections rarely develop resistance to combination drug therapy

Fungal infections rarely develop resistance to combination drug therapy

Researchers at the University of Toronto have discovered that Candida albicans -- a leading cause of potentially fatal hospital-acquired infections -- rarely develops resistance to combination drug therapy and, when it becomes resistant, it also becomes less dangerous. [More]
Leading microbiologist warns of killer fungi’s increasing threat

Leading microbiologist warns of killer fungi’s increasing threat

A leading microbiologist has warned of the increasing threat that killer fungi poses to humans and the environment. [More]
3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody ("mAb") targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea. [More]
Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Long known for its ability to help organisms successfully adapt to environmentally stressful conditions, the highly conserved molecular chaperone heat-shock protein 90 (HSP90) also enables estrogen receptor-positive (ER+) breast cancers to develop resistance to hormonal therapy. [More]
3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia. [More]
LSU Health New Orleans professor awarded $1.8 million grant to target intra-abdominal infections

LSU Health New Orleans professor awarded $1.8 million grant to target intra-abdominal infections

Mairi Noverr, PhD, Associate Professor of Prosthodontics at LSU Health New Orleans School of Dentistry's Center of Excellence in Oral Biology, has been awarded a $1.8 million grant by the National Institute of Allergy and Infectious Diseases. [More]
Advertisement
Advertisement